HCWB HCW Biologics
- 1.500
- -0.104-6.46%
HCW Biologics News
HCW Biologics Receives Buy Rating: Strong Financial Position and Promising Clinical Data Validate Investment Opportunity
Analysts Are Bullish on Top Healthcare Stocks: HCW Biologics (HCWB), Urogen Pharma (URGN)
Promising Phase 1 Results and Potential Synergies With PD-1 Inhibitors Bolster Buy Rating for HCW Biologics
Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Cochlear Limited (OtherCHEOF)
Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Arrowhead Pharmaceuticals (ARWR)
EF Hutton Assumes HCW Biologics at Buy, Announces Price Target of $9
JonesTrading Remains a Buy on HCW Biologics (HCWB)
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and HCW Biologics (HCWB)
EF Hutton Reiterates Buy on HCW Biologics, Maintains $9 Price Target
Maxim Group Remains a Buy on HCW Biologics (HCWB)
HCW Biologics (HCWB) Receives a Buy From Maxim Group
EF Hutton Reiterates Buy on HCW Biologics, Maintains $9 Price Target
JonesTrading Reaffirms Their Buy Rating on HCW Biologics (HCWB)
EF Hutton Reiterates Buy on HCW Biologics, Maintains $9 Price Target
JonesTrading Keeps Their Buy Rating on HCW Biologics (HCWB)
Maxim Group Sticks to Its Buy Rating for HCW Biologics (HCWB)
HCW Biologics Analyst Ratings
JonesTrading Initiates Coverage On HCW Biologics With Buy Rating, Announces Price Target of $8
Maxim Group Remains a Buy on HCW Biologics (HCWB)
Analysis
Price Target
No Data
